What is claimed is:

1. A method of administering gene therapy or delivering recombinant or foreign polynucleotides to mammalian cells or organisms, comprising the steps of:

a) creating a genetically engineered baculovirus having a deletion, inactivation or downregulation of an envelope protein gene of a progenitor baculovirus, from which said engineered baculovirus is derived, wherein said genetically engineered virus is supplied, in trans or cis, with a heterologous envelope protein or a protein or other molecule that facilitates entry of said engineered baculovirus into a cell that is not normally a host of said progenitor baculoviru;

b) further modifying said engineered baculovirus to express a gene therapy agent or recombinant or foreign polynucleotide; and

c) delivering said modified baculovirus into said mammalian cell or organism.

2. The method of claim 1, wherein said genetically engineered baculovirus has a property of more efficient entry into a non-host cell than said progenitor baculovirus, from which said engineered baculovirus is derived.

3. The method of claim 1, wherein said genetically engineered baculovirus has a property of more specific targeting of said engineered baculovirus to a specific cell type than said progenitor baculovirus, from which said engineered baculovirus is derived.

4. The method of claim 1, wherein said genetically engineered baculovirus has a property of more effective evasion of mammalian immune system recognition or inactivation than said progenitor baculovirus, from which said engineered baculovirus is derived.

5. The method of claim 1, wherein said genetically engineered baculovirus is engineered to express an envelope protein from Vesicular Stomatitis Virus.

6. The method of claim 5, wherein said envelope protein from Vesicular Stomatitis Virus is VSV-G protein.

7. A method of protein expression, comprising the steps of:

a) creating a genetically engineered baculovirus having a deletion, inactivation or dowenregulation of an envelope protein gene of a progenitor baculovirus, from which said engineered baculovirus is derived, wherein said genetically engineered virus is supplied, in trans or cis, with a heterologous envelope protein or a protein or other molecule that facilitates entry of said engineered baculovirus into a cell that is not normally a host of said progenitor baculovirus;

b) further modifying said engineered baculovirus to express a recombinant or foreign polynucleotide; and

c) delivering said modified baculovirus into a suitable cell for expression of said recombinant or foreign protein by said engineered baculovirus.

8. The genetically engineered baculovirus of claim 1, wherein said genetically engineered baculovirus infects and replicates in at least one permissive insect cell host of said progenitor baculovirus.

9. The genetically engineered baculovirus of claim 8, wherein said progenitor baculovirus envelope protein is gp64 or a homologous envelope glycoprotein.